Literature DB >> 17389319

Efficacy of propafenone in paramyotonia congenita.

E Alfonsi1, I M Merlo, M Tonini, S Ravaglia, R Brugnoni, A Gozzini, A Moglia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17389319     DOI： 10.1212/01.wnl.0000257825.29703.e8

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  12 in total

Review 1.  Diagnostics and therapy of muscle channelopathies--Guidelines of the Ulm Muscle Centre.

Authors:  F Lehmann-Horn; K Jurkat-Rott; R Rüdel
Journal:  Acta Myol       Date:  2008-12

2.  SCN4A variants and Brugada syndrome: phenotypic and genotypic overlap between cardiac and skeletal muscle sodium channelopathies.

Authors:  Véronique Bissay; Sophie C H Van Malderen; Kathelijn Keymolen; Willy Lissens; Uschi Peeters; Dorien Daneels; Anna C Jansen; Gudrun Pappaert; Pedro Brugada; Jacques De Keyser; Sonia Van Dooren
Journal:  Eur J Hum Genet       Date:  2015-06-03       Impact factor: 4.246

Review 3.  Sodium channelopathies of skeletal muscle result from gain or loss of function.

Authors:  Karin Jurkat-Rott; Boris Holzherr; Michael Fauler; Frank Lehmann-Horn
Journal:  Pflugers Arch       Date:  2010-03-17       Impact factor: 3.657

Review 4.  Treatment of neuromuscular channelopathies: current concepts and future prospects.

Authors:  James C Cleland; Robert C Griggs
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 5.  The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Authors:  E Matthews; D Fialho; S V Tan; S L Venance; S C Cannon; D Sternberg; B Fontaine; A A Amato; R J Barohn; R C Griggs; M G Hanna
Journal:  Brain       Date:  2009-11-16       Impact factor: 13.501

6.  Cannabidiol inhibits the skeletal muscle Nav1.4 by blocking its pore and by altering membrane elasticity.

Authors:  Koushik Choudhury; Tagore S Bandaru; Mohamed A Fouda; Kaveh Rayani; Mohammad-Reza Ghovanloo; Radda Rusinova; Tejas Phaterpekar; Karen Nelkenbrecher; Abeline R Watkins; Damon Poburko; Jenifer Thewalt; Olaf S Andersen; Lucie Delemotte; Samuel J Goodchild; Peter C Ruben
Journal:  J Gen Physiol       Date:  2021-05-03       Impact factor: 4.086

7.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

Review 8.  Drug treatment for myotonia.

Authors:  J Trip; G Drost; B G M van Engelen; C G Faber
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

9.  State of the art in hereditary muscle channelopathies.

Authors:  K Jurkat-Rott; F Lehmann-Horn
Journal:  Acta Myol       Date:  2010-10

10.  Skeletal muscle na channel disorders.

Authors:  Dina Simkin; Saïd Bendahhou
Journal:  Front Pharmacol       Date:  2011-10-14       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.